Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 405 (CSE: $PMED.C) (TSX: $FIRE.TO) (CSE: $HARV.C) (CSE: $SHRM.C), (CSE: $BILZ.C)
Delta, Kelowna, BC,April 28th, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/04281PMED-FIRE-HARV-SHRM-BILZ.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today’s podcast will be looking at a few public company announcements.
Predictmedix Inc. (CSE: PMED) (OTCQB: PMEDF) announced that it has filed Patent Application Number 63012510 – Artificial Intelligence driven rapid screening system for infectious diseases, such as SARS-CoV-2 virus responsible for COVID-19, with the United States Patent and Trademark Office.
COVID-19 pandemic has turned into a threat for global security and economic stability, resulting in unprecedented job losses not seen since the great depression. Identification and tracking of an infectious disease or an outbreak of a global pandemic is a critical element of controlling the spread of disease across geographical areas. Furthermore, infectious diseases such as COVID-19 are likely to return in waves until there is mass vaccination or development of population level immunity. As such, there is a significant urgent need to have mass screening technologies which can identify potential COVID-19 cases without the need for human intervention and can be deployed in places where there is movement of large number of people. For instance, but not limited to, healthcare, transit hubs, airports, malls, shopping centers, casinos, concerts, arenas and office buildings.
One of the primary factors leading to the outbreak of COVID-19 virus has been the relative lack of rapid screening tools for the masses. The lack of such tools has resulted in a failed containment effort which led to a global pandemic and an unprecedented economic disruption.
Predictmedix has developed a proprietary technology (patent pending) to screen for potential cases of COVID-19 and other related infectious diseases. There is no need for any bodily fluids and there is no human exposure as the screening is carried out using multispectral cameras which can be installed at any facility.
The artificial intelligence ("AI") powered technology utilizes multispectral imaging with a focus on visual spectral imaging along with infrared thermography to identify cases which are suspected of COVID-19. The AI technology monitors and identifies potential presence of COVID-19 associated symptoms such as fatigue, headache, coughing, sneezing, blood flow, sweat gland activation, metabolism, fever along with other key determinant factors.
The technology can be deployed using multispectral cameras in facilities where there is large movement of people to identify potential COVID-19 cases and limit exposure, thereby limiting infection. The data collected is brought into a central server / cloud for analysis and alerts are sent in case of a positive detection.
"There is not going to be a medical breakthrough such as a vaccine or drug that is going to solve the COVID-19 problem soon. We have applied travel bans and physical distancing orders to our society which has had a devastating impact on our economy and way of life. With Predictmedix's AI technology we could be much more tactful in our approach. Strategically placed multispectral cameras, installed in airports for example, could collect biometric data on individual passengers en masse. Predictmedix's AI technology can analyze that data and predict which passengers should be flagged for secondary screening, definitive testing or even quarantine while allowing others to travel unimpeded. This could allow our societies and economies to mobilize again while preventing further spread of this disease." said Dr. Alexander Bardon, an Emergency Medicine physician in Ontario and an advisor to Predictmedix.
7ACRES, a division of The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) announced today that it has launched a new brand extension called 7ACRES Craft Collective.
7ACRES Craft Collective brings together some of the most sought-after cultivars, with a focus on high THC and exceptional quality, from the country's most talented craft producers. With every drop, Craft Collective will issue small batches of craft cannabis, hand selected for specific provinces based on the preferences and unique tastes of cannabis consumers. The first strain launched under 7ACRES Craft Collective will be a Pink Kush that is grown, and exclusively available, in British Columbia.
"We are excited to launch 7ACRES Craft Collective as a way to bring new and unique craft cannabis strains to consumers. We've identified an opportunity to work with smaller, craft producers to quickly introduce new and exciting cultivars to consumers," said Joel Toguri, Chief Revenue Officer at Supreme Cannabis. "While we continue to expand our in-house growing capabilities, we have engaged small craft growers who have a passion for the plant to bring their cannabis to market under 7ACRES Craft Collective. We are excited to bring our first offering to British Columbia and introduce 7ACRES Craft Collective to consumers who have a passion for locally grown craft-cannabis."
Craft cannabis is traditionally grown using small batch micro-growing practices for the sole purpose of producing high quality cannabis with unique flavours, and exotic, ultra-pungent expressions of the plant. 7ACRES has found and continues to identify talented producers who are growing superior cannabis across Canada. The goal of 7ACRES Craft Collective is to bring the highest quality, craft cannabis to the legal market and work with passionate growers to meet the selective tastes of cannabis consumers.
7ACRES Craft Collective Pink Kush is a high THC, small batch craft cultivar with intense fuel notes. 7ACRES experts selected this particular Pink Kush for its intensely pungent fuel notes, high THC and dense bud structure; a true designer pink. A terpene rich indica dominant hybrid that fills the room with heavy diesel notes and hints of flowery perfume and citrus. This Pink Kush strain is a descendant of OG Kush and was grown at an indoor craft facility in British Columbia.
Harvest Health & Recreation Inc. (CSE: HARV) (OTCQX: HRVSF) today announced plans to divest select retail assets in California to Hightimes Holding Corp. Harvest and its affiliates intend to sell a portfolio of equity and assets with respect to 13 operational and planned dispensaries in California for total consideration including up to $5 million in cash, $7.5 million as a one-year promissory note with 10% interest, and $67.5 million in Series A Preferred Stock issued by High Times. Harvest will retain select retail dispensaries and licenses for potential retail locations in California following completion of this transaction.
"This planned divestment of select retail assets in California allows Harvest to focus on optimizing operations and expanding assets in core markets such as Arizona, Florida, Maryland, and Pennsylvania while retaining a smaller retail presence in California" said Chief Executive Officer Steve White. "We will continue to examine the strategic value of our assets and streamline operations as we move toward achieving our profitability goals."
The transaction is expected to close by June 30, 2020 subject to various closing conditions and contingencies including regulatory approvals and availability of capital consideration. Assets may be excluded from the divestment plan if required approvals are not obtained resulting in an adjustment to the total consideration.
Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, announced that it has been selected as the Headline Partner for Prohibition Partners LIVE’s PSYCH: The Psychedelics Symposium, scheduled to take place June 22 – 23, 2020.
PSYCH is architected and moderated by Prohibition Partners LIVE and will be this year’s most significant psychedelics virtual conference, bringing together key stakeholders at the forefront of the industry to share unparalleled insights and intelligence. Thought leaders from the worlds of health care, science and business will present their latest findings and expert analysis on the state of the industry from unique locations across the globe.
While cannabis has paved much of the way for psychedelics in terms of legal progress and changing public perception, psychedelics as medicines are backed by a comparatively more powerful knowledge base. The potential for psychedelics in innovative treatments for numerous high-prevalence health problems has become the next major focus.
Champignon quickly established itself as an industry leader within this emerging arena and boasts an impressive portfolio of accretive assets that target key segments in the psychedelic as medicines for mental health conditions vertical:
- Psychedelic medicines clinic platform;
- Novel drug discovery; and
- Formulations and delivery systems.
PSYCH participants will have the opportunity to attend live-streamed keynotes and panels from over 150 CEOs, policymakers and cultural leaders, and gain unrivalled access to some of the most influential brands and businesses in the world as they discuss how cannabis and psychedelics will affect our future.
Prohibition Partners’ Managing Director Stephen Murphy stated, "The impact of COVID-19 has put greater emphasis on the importance of mental health. Consumers are looking for options to improve their mental health and, as the body of evidence mounts for psychedelics, the healthcare industry is responding with solutions. We’re delighted to partner with Champignon Brands on PSYCH and support their vision of improving mental health via psychedelics.”
Champignon invites all current and prospective shareholders to join PSYCH on June 22 – 23 to discover the latest developments in the psychedelic industry, learn from world-renowned speakers and engage with a network of industry-leading professionals.
IGNITE International Brands, Ltd. (CSE:BILZ) (OTCQX: BILZF), a global consumer packaged goods brand, announced that it is ramping up efforts to help in the fight against the current coronavirus pandemic. Product donations and new COVID-19 response products have become priorities for the Company as it joins in the global effort to eradicate the virus.
IGNITE’s new line of COVID-19 response products includes masks, gloves, hand sanitizer and sanitizing surface spray. To develop these products, IGNITE has partnered with LCF Labs. LCF Labs is in the business of contract manufacturing and packing for a growing number of customers with leading brands in the vape industry; however, partially as a result of its agreement with its partnership with IGNITE, LCF made a transition to manufacturing and packing hand sanitizer to support the fight against COVID-19.
“Our customers and their well-being are our number one priority always. As an international brand our customers span across the globe, and we’re trying to support the global fight against the COVID-19 pandemic,” said IGNITE President, Curtis Heffernan. “We’re thrilled to have a partner like LCF to navigate the current industry climate and aid in efforts to prevent further spread of COVID-19.”
IGNITE continues to focus on monitoring the latest COVID-19 updates and is taking all appropriate actions to operate safely. To prevent the spread of COVID-19, LCF Labs together with IGNITE will donate thousands of hand sanitizers to first responders and hospitals.
IGNITE has committed to donating 5,000 units of its CBD infused lip balm to the Corona Care Challenge in the United Kingdom. This organization, together with IGNITE will continue to support all the incredible frontline staff at the NHS across London and Greater London.
IGNITE has also committed to donating $25,000 worth of COVID-19 prevention products to local Los Angeles organizations.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Contact Investorideas.com
800 665 0411
No comments:
Post a Comment